Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis

P. Barcelo, O. Wuhl, E. Servitge, A. Rousaud, C. Y C Pak

Research output: Contribution to journalArticle

273 Citations (Scopus)

Abstract

In an attempt to document the efficacy of potassium citrate in stone formation, 57 patients with active lithiasis (2 or more stones during the preceding 2 years) and hypocitraturia were randomly allocated into 2 groups, with 1 group taking 30 to 60 mEq. potassium citrate daily in wax matrix tablet formation and the other group receiving placebo. In 18 patients receiving potassium citrate for 3 years stone formation significantly declined after treatment from 1.2 ± 0.6 to 0.1 ± 0.2 per patient year (p <0.0001), in 13 patients (72%) the disease was in remission and all patients showed a reduced stone formation rate individually. In contrast, 20 patients taking placebo medication for 3 years showed no significant change in stone formation rate (1.1 ± 0.4 to 1.1 ± 0.3 per patient year) and in only 4 patients (20%) was the disease in remission. The stone formation rate during potassium citrate treatment was significantly lower than during the placebo treatment (0.1 ± 0.2 versus 1.1 ± 0.3 per patient year, p <0.001). Potassium citrate therapy caused a significant increase in urinary citrate, pH and potassium, whereas placebo did not. Adverse reactions to potassium citrate were mild causing only 2 patients in the potassium citrate group and 1 in the placebo group to withdraw from the study. In summary, our randomized trial showed the efficacy of potassium citrate in preventing new stone formation in idiopathic hypocitraturic calcium nephrolithiasis.

Original languageEnglish (US)
Pages (from-to)1761-1764
Number of pages4
JournalJournal of Urology
Volume150
Issue number6
StatePublished - 1993

Fingerprint

Potassium Citrate
Nephrolithiasis
Double-Blind Method
Calcium
Placebos
Lithiasis
Waxes
Therapeutics
Tablets

Keywords

  • calcium
  • calculi
  • potassium

ASJC Scopus subject areas

  • Urology

Cite this

Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. / Barcelo, P.; Wuhl, O.; Servitge, E.; Rousaud, A.; Pak, C. Y C.

In: Journal of Urology, Vol. 150, No. 6, 1993, p. 1761-1764.

Research output: Contribution to journalArticle

Barcelo, P, Wuhl, O, Servitge, E, Rousaud, A & Pak, CYC 1993, 'Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis', Journal of Urology, vol. 150, no. 6, pp. 1761-1764.
Barcelo, P. ; Wuhl, O. ; Servitge, E. ; Rousaud, A. ; Pak, C. Y C. / Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. In: Journal of Urology. 1993 ; Vol. 150, No. 6. pp. 1761-1764.
@article{566821500e7e460ba11a14e8b37d8ce1,
title = "Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis",
abstract = "In an attempt to document the efficacy of potassium citrate in stone formation, 57 patients with active lithiasis (2 or more stones during the preceding 2 years) and hypocitraturia were randomly allocated into 2 groups, with 1 group taking 30 to 60 mEq. potassium citrate daily in wax matrix tablet formation and the other group receiving placebo. In 18 patients receiving potassium citrate for 3 years stone formation significantly declined after treatment from 1.2 ± 0.6 to 0.1 ± 0.2 per patient year (p <0.0001), in 13 patients (72{\%}) the disease was in remission and all patients showed a reduced stone formation rate individually. In contrast, 20 patients taking placebo medication for 3 years showed no significant change in stone formation rate (1.1 ± 0.4 to 1.1 ± 0.3 per patient year) and in only 4 patients (20{\%}) was the disease in remission. The stone formation rate during potassium citrate treatment was significantly lower than during the placebo treatment (0.1 ± 0.2 versus 1.1 ± 0.3 per patient year, p <0.001). Potassium citrate therapy caused a significant increase in urinary citrate, pH and potassium, whereas placebo did not. Adverse reactions to potassium citrate were mild causing only 2 patients in the potassium citrate group and 1 in the placebo group to withdraw from the study. In summary, our randomized trial showed the efficacy of potassium citrate in preventing new stone formation in idiopathic hypocitraturic calcium nephrolithiasis.",
keywords = "calcium, calculi, potassium",
author = "P. Barcelo and O. Wuhl and E. Servitge and A. Rousaud and Pak, {C. Y C}",
year = "1993",
language = "English (US)",
volume = "150",
pages = "1761--1764",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis

AU - Barcelo, P.

AU - Wuhl, O.

AU - Servitge, E.

AU - Rousaud, A.

AU - Pak, C. Y C

PY - 1993

Y1 - 1993

N2 - In an attempt to document the efficacy of potassium citrate in stone formation, 57 patients with active lithiasis (2 or more stones during the preceding 2 years) and hypocitraturia were randomly allocated into 2 groups, with 1 group taking 30 to 60 mEq. potassium citrate daily in wax matrix tablet formation and the other group receiving placebo. In 18 patients receiving potassium citrate for 3 years stone formation significantly declined after treatment from 1.2 ± 0.6 to 0.1 ± 0.2 per patient year (p <0.0001), in 13 patients (72%) the disease was in remission and all patients showed a reduced stone formation rate individually. In contrast, 20 patients taking placebo medication for 3 years showed no significant change in stone formation rate (1.1 ± 0.4 to 1.1 ± 0.3 per patient year) and in only 4 patients (20%) was the disease in remission. The stone formation rate during potassium citrate treatment was significantly lower than during the placebo treatment (0.1 ± 0.2 versus 1.1 ± 0.3 per patient year, p <0.001). Potassium citrate therapy caused a significant increase in urinary citrate, pH and potassium, whereas placebo did not. Adverse reactions to potassium citrate were mild causing only 2 patients in the potassium citrate group and 1 in the placebo group to withdraw from the study. In summary, our randomized trial showed the efficacy of potassium citrate in preventing new stone formation in idiopathic hypocitraturic calcium nephrolithiasis.

AB - In an attempt to document the efficacy of potassium citrate in stone formation, 57 patients with active lithiasis (2 or more stones during the preceding 2 years) and hypocitraturia were randomly allocated into 2 groups, with 1 group taking 30 to 60 mEq. potassium citrate daily in wax matrix tablet formation and the other group receiving placebo. In 18 patients receiving potassium citrate for 3 years stone formation significantly declined after treatment from 1.2 ± 0.6 to 0.1 ± 0.2 per patient year (p <0.0001), in 13 patients (72%) the disease was in remission and all patients showed a reduced stone formation rate individually. In contrast, 20 patients taking placebo medication for 3 years showed no significant change in stone formation rate (1.1 ± 0.4 to 1.1 ± 0.3 per patient year) and in only 4 patients (20%) was the disease in remission. The stone formation rate during potassium citrate treatment was significantly lower than during the placebo treatment (0.1 ± 0.2 versus 1.1 ± 0.3 per patient year, p <0.001). Potassium citrate therapy caused a significant increase in urinary citrate, pH and potassium, whereas placebo did not. Adverse reactions to potassium citrate were mild causing only 2 patients in the potassium citrate group and 1 in the placebo group to withdraw from the study. In summary, our randomized trial showed the efficacy of potassium citrate in preventing new stone formation in idiopathic hypocitraturic calcium nephrolithiasis.

KW - calcium

KW - calculi

KW - potassium

UR - http://www.scopus.com/inward/record.url?scp=0027720279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027720279&partnerID=8YFLogxK

M3 - Article

C2 - 8230497

AN - SCOPUS:0027720279

VL - 150

SP - 1761

EP - 1764

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -